Eli Lilly Posts Strong 2Q Earnings

Your next video will start in

Recommended Videos

  • Info

  • Comments


July 24 (Bloomberg) -- Bloomberg's Olivia Sterns and Dominic Chu discuss Eli Lilly earnings and the company losing patent protection on Cymbalta in December on Bloomberg Television's "Money Moves." (Source: Bloomberg)

Olivia, what have you learned?

This is a strong center results.

Net income rose 31%. but i think the real reason we are seeing that is they raised the guidance, and they did that in an environment where they are about to fall off of a patent cliff.

These drug companies always faced these patent cliffs.

Sombalta is a big one for them.

Yes, and i will talk about that in a minute, but i asked one about how he beat on the top and bottom line.

6% top line was driven by the performance of a number of products that offset some of the residual negative effects of the zyprexa patent, which occurred in 2011. cymbalta and cialis both grew.

As you know, he was out due to heart surgery back in may.

Let's talk about back -- that cymbalta.

What did we learn about that?

$5 billion in sales, and they are about to lose the patent, so next year is going to be a trough year.

That is why now it really matters what is in the pipeline.

They have got four drugs that they are going to bring, a broad spectrum diabetes drug, and also a big bet on alzheimer's. i know that you did speak about what is happening with the affordable care act.

Just paraphrase for us some of the things that he told you.

He is an interesting guy to talk to, because he used to be the head of pharma, and what he said is he has basically already felt the brunt of this.

The guy that knows a lot about the affordable care act.

Olivia sterns, thank you.

This text has been automatically generated. It may not be 100% accurate.


BTV Channel Finder


ZIP is required for U.S. locations

Bloomberg Television in   change